Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the children's oncology group

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6858-6866

  Villablanca, Judith G ^a   London, Wendy B ^b,c   Naranjo, Arlene ^c,d   McGrady, Patrick ^c,d   Ames, Matthew M ^e   Reid, Joel M ^e   McGovern, Renee M ^e   Buhrow, Sarah A ^e   Jackson, Hollie ^a   Stranzinger, Enno ^f   Kitchen, Brenda J ^g   Sondel, Paul M ^h   Parisi, Marguerite T ⁱ   Shulkin, Barry ^j   Yanik, Gregory A ^g   Cohn, Susan L ^k   Patrick Reynolds, C ^l  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ SEATTLE CHILDREN S HOSPITAL   (United States)

^j ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

^l TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; ISOTRETINOIN;

ABDOMINAL PAIN; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER INFILTRATION; CANCER MORTALITY; CANCER PAIN; CANCER RELAPSE; CANCER SURVIVAL; CATHETER INFECTION; CHEMOTHERAPY INDUCED EMESIS; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DYSPNEA; EPISTAXIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOXIA; INFANT; INFECTION; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LIVER FAILURE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUROBLASTOMA; NEUTROPHIL COUNT; NIGHT BLINDNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SCINTISCANNING; SIDE EFFECT; STEADY STATE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TUMOR GROWTH; WEIGHT REDUCTION;

3-IODOBENZYLGUANIDINE; ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; CAPSULES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FENRETINIDE; HUMANS; INFANT; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 80455162314     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0995     Document Type: Article

References (46)

1. Gudas LJ SM, Roberts AB. Cellular biology and biochemistry of the retinoids. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids. New York: Raven Press; 1994. p. 443-520.
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73. (Pubitemid 29480654)
3. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 2009;27:1007-13.
4. Yu AL, GIlman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;14:1324-34.
5. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol 2000;35:597-602.
6. Di Vinci A, Geido E, Infusini E, Giaretti W. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide. Int J Cancer 1994;59:422-6. (Pubitemid 24331837)
7. Mariotti A, Marcora E, Bunone G, Costa A, Veronesi U, Pierotti MA, et al. N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 1994;86:1245-7. (Pubitemid 24253701)
8. Ziv Y, Gupta MK, Milson JW, Vladisavljevic A, Brand M, Fazio VW. The effect of tamoxifen and fenretinimide on human colorectal cancer cell lines in vitro. Anticancer Res 1994;14:2005-9.
9. Hsieh TC, Ng C, Wu JM. The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochem Mol Biol Int 1995;37:499-506. (Pubitemid 26177904)
10. Kazmi SM, Plante RK, Visconti V, Lau CY. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Can Res 1996;56:1056-62. (Pubitemid 26065400)
11. Supino R, Crosti M, Clerici M, Warlters A, Cleris L, Zunino F, et al. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 1996;65:491-7. (Pubitemid 26084403)
12. Kalemkerian GP, Slusher R, Ramalingam S, Gadgeel S, Mabry M. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Nat Cancer Inst 1995;87:1674-80.
13. Ohlmann CH, Jung C, Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl) retinamide] sufficient for cancer therapy? Int J Cancer 2002;100:520-6. (Pubitemid 34816151)
14. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Formelli F, et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53:6036-41.
15. Ozpolat B, Tari AM, Mehta K, Lopez-Berestein G. Nuclear acid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)- induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma 2004;45:979-85. (Pubitemid 38444675)
16. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-46. (Pubitemid 29330552)
17. Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, et al. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem 2002;277:49531-7. (Pubitemid 36014391)
18. Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, et al. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther 2008;7:2967-76.
19. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000;92:1897-909. (Pubitemid 32036920)
20. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide- induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1191-8. (Pubitemid 27350028)
21. Asumendi A, Morales MC, Alvarez A, Aréchaga J, Pérez-Yarza G. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Br J Cancer 2002;86:1951-6.
22. Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer 2001;94:314-21. (Pubitemid 32906059)
23. Villa ML, Ferrario E, Trabattoni D, Formelli F, De Palo G, Magni A, et al. Retinoids, breast cancer and NK cells. Br J Cancer 1993;68:845-50. (Pubitemid 23315212)
24. Zhao Z, Matsuura T, Popoff K, Ross AC. Effects of N-(4-hydroxyphenyl)- retinamide on the number and cytotoxicity of natural killer cells in vitamin-A-sufficient and -deficient rats. Nat Immun 1994;13: 280-8. (Pubitemid 24326647)
25. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006;24:3423-30. (Pubitemid 46638899)
26. Jasti BR, LoRusso PM, Parchment RE, Wozniak AJ, Flaherty LE, Shields AF, et al. Phase I clinical trial of fenretinide (NSC374551) in advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2001;20:122a (abstract # 485).
27. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2000;18:4067-76. (Pubitemid 32038399)
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
29. Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, et al. A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995;31A:256-61.
30. Bugge CJL, Rodriguez LC, Vane FM: Determination of isotretinoin or etretinate and their major metabolites in human blood by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1985;3:269-77. (Pubitemid 15020876)
31. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-42. (Pubitemid 23304631)
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
33. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II: Analysis and examples. Br J Cancer 1977;35:1-39. (Pubitemid 8018922)
34. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
35. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, et al. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995;55:853-61.
36. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9. (Pubitemid 30306028)
37. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-91. (Pubitemid 46606329)
38. Yanik GA, Parisi MT, Shulkin B, Naranjo A, Kreissman S, London W, et al. Analyses of mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma. A COG Children's Oncology Group (A3973) report [abstract]. Proc ANR 2010; p. 102 (abstract #PL30).
39. Yanik GA, Parisi MT, Naranjo A, Matthay KK, London WB, McGrady PW, et al. MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study [abstract #9516]. ASCO Ann Meeting Proc 2010;28:682s.
40. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010;28:4969-75.
41. Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011;29:208-13.
42. Doose DR, Minn FL, Stellar S, Nayak RK. Effects of meals and meal composition on the bioavailability of fenretinide. J Clin Pharmacol 1992;32:1089-95. (Pubitemid 23033660)
43. Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, et al. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 2007;13:3079-86. (Pubitemid 46849585)
44. Marachelian A, Kang MH, Hwang K, Villablanca JG, Groshen S, Matthay KK, et al. Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial [abstract # 10009]. ASCO Ann Meeting Proc 2009;27:15s.
45. Kang MH, Marachelian A, Villablanca JG, Maris JM, Ames M, Reid JM, et al. Fenretinide (4-HPR) orally formulated in Lym-X-Sorb(LXS) lipid matrix or as an intravenous emulsion increased 4-HPR systemic exposure in patients with Recurrent or Resistant Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Consortium Trial [abstract]. Proc ANR 2010; p. 123. (abstract # OR57).
46. Morbacher A, Gutierrez M, Murgo AJ, Kummar S, Reynolds CP, Maurer BJ, et al. Phase I trial of fenretinide (4-HPR) intravenous emulsion for hematological malignancies [abstract]. Am Soc Hematol, Blood 2007;110:2581.